Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

Go back to Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
(NASDAQ: PRME) Delayed: 3.47 +0.26 (8.10%)
Previous Close $3.21    52 Week High $21.72 
Open $3.56    52 Week Low $18.36 
Day High $3.72    P/E N/A 
Day Low $3.26    EPS $0.00 
Volume 8,851,867